



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number:

0 460 239 A1

EUROPEAN PATENT APPLICATION
published in accordance with Art.
158(3) EPC

- ②¹ Application number: 91901536.2

- Ⓢ Int. Cl.⁵: **C07D 237/10**, C07D 317/32,
C07C 237/22, A61K 31/385

- ② Date of filing: 26.12.90

- ⑥ International application number:
PCT/JP90/01704

- Ⓒ International publication number:
WO 91/09851 (11.07.91 91/15)

- ③ Priority: 27.12.89 JP 336247/89
13.08.90 JP 211682/90

- ④3 Date of publication of application:
11.12.91 Bulletin 91/50

- ⑧ Designated Contracting States:
AT BE CH DE DK ES FR GB IT LI LU NL SE

- ⑦¹ Applicant: **Japan Tobacco Inc.**
4-12-62 Higashishinagawa
Shinagawa-ku, Tokyo 140(JP)

- (72) Inventor: **HARUTA, Jun-ichi**, c/o
Pharmaceutical Research Labs
Japan Tobacco Inc., 6-2, Umegaoka,
Midori-ku
Yokohama-shi, Kanagawa-ken 227(JP)
Inventor: **TANAKA, Masahiro**, c/o
Pharmaceutical Research Labs
Japan Tobacco Inc., 6-2, Umegaoka,

Midori-ku

Yokohama-shi, Kamagawa-ken 227(JP)

Inventor: **UCHIDA, Itsuo, c/o Pharmaceutical Research Labs.**

**Japan Tobacco Inc., 6-2, Umegaoka,
Midori-ku**

Yokohama-shi, Kanagawa-ken 227(JP)

Inventor: **OHTA, Akira, c/o Toxicology Research Laboratory**

Japan Tobacco Inc., 23, Naganuki

Hadano-shi, Kanagawa-ken 257(JP)

Inventor: **HARA, Shin, c/o Toxicology**

Research Laboratory

Japan Tobacco Inc., 23, Naganuki

Hadano-shi, Kanagawa-ken 257(JP)

- 74 Representative: **Reinhard, Skuhra, Weise**
Friedrichstrasse 31
W-8000 München 40(DE)

- 54 1,3,2-DIOXATHIOLANE OXIDE DERIVATIVE.

- 57) A 1,3,2-dioxathiolane oxide derivative of general formula (I) wherein x represents -S(O)- or -S(O)₂-; R¹ represents hydrogen, alkali metal atom, benzyl or lower alkyl; R² represents lower alkyl which may be substituted by methylthio, or benzyl; and R³ and R⁴ may be the same or different from each other and each represents hydrogen, C₁ to C₁₀ alkyl, guanidyl-substituted lower alkyl, C₃ to C₆ cycloalkyl, phenyl, benzyl or phenoethyl, or R³ and R⁴ are combined together to represent alkylene.



[Technical Field]

The present invention relates to a novel 1,3,2-dioxathiolane oxide derivative and its intermediate compound. More particularly, the present invention relates to a novel 1,3,2-dioxathiolane oxide derivative having good inhibitory activity against thiol proteases such as calcium-dependent neutral protease (CANP) and cathepsins B, H, and L, and also relates to a 1,3-dioxolane derivative and a 1,2-diol derivative useful to prepare the 1,3,2-dioxathiolane derivative.


[Background Art]

Proteolytic enzymes represented by CANP and including, e.g., cathepsin B, papain, ficin, bromelain, and bromelan are generally called thiol proteases because they have a thiol group at an active center. On the other hand, it is known that substances having CANP inhibition activity not only specifically affect the thiol group of the CANP to inhibit its activity but also have an inhibitory effect on other thiol proteases.


Therefore, substances capable of inhibiting the thiol proteases such as CANP and cathepsin B are expected to use in the cure, mitigation, treatment, or prevention of diseases to which these proteases are related, e.g., myotonic dystrophy, inflammation, renal hypertension, cataract, myocardial infarct, a virus infectious disease, a malignant tumor, osteoporosis, and an allergic disease.

Conventionally known examples of a compound having thiol protease inhibition activity are E-64 as a mold metabolite, a series of epoxy succinic acid derivatives such as E-64-c as derivatives of E-64, and aldehyde derivatives of leupeptin and antipine belonging to a secondary metabolite of an actinomycete.

E-64 is an epoxysuccinic acid derivative obtained from a bran solid culture of an *Aspergillus japonicus* TPR-64 strain and represented by the following formula (e.g., Published Unexamined Japanese Patent Application No. 52-23021 and Published Examined Japanese Patent Application No. 64-5031):



Both of E-64-c and loxistatin as its ethylester are derivatives of the above E-64 and represented by the following formula (e.g., Published Unexamined Japanese Patent Application No. 55-115878):




The above two compounds, especially, loxistatin has attracted attention due to its effect as a proteolytic enzyme inhibitor and therefore is currently being studied to realize a practical use as a treating agent against muscular dystrophy and the like.

[Disclosure of Invention]

It is an object of the present invention to provide a novel compound effective in the cure, mitigation, treatment, or prevention of diseases as described above. The present inventors have made extensive studies to achieve this object and found that a novel 1,3,2-dioxathiolane oxide derivative has high specific inhibitory activity against a thiol protease, and established the present invention.

Novel 1,3,2-dioxathiolane oxide derivative according to the present invention is represented by the following formula [I]:




wherein

- X means -S(O)- or -S(O)₂-.
- R¹ means a hydrogen atom, an alkali metal atom, a benzyl group, or a lower alkyl group.
- R² means a lower alkyl group which may be substituted with a methylthio group, or a benzyl group.
- R³ and R⁴ may be the same or different and independently mean a hydrogen atom, an alkyl group having one to ten carbon atoms, a lower alkyl group substituted with a guanidyl group, a cycloalkyl group having 3 to 6 carbon atoms, a phenyl group, a benzyl group, or a phenethyl group, or together mean an alkylene group.


The lower alkyl group represented by R¹ and R² means a straight-chain or branched alkyl group having one to five, and preferably, one to four carbon atoms. Examples of this alkyl group are a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a sec-butyl group, and a tert-butyl group etc.

The alkyl group represented by R³ and R⁴ means a straight-chain or branched alkyl group having one to ten carbon atoms. Examples of this alkyl group are a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a hexyl group, an isohexyl group, a heptyl group, an isoheptyl group, an octyl group, an isooctyl group, a nonyl group, an isononyl group, a decyl group, and an isodecyl group. The alkylene group means a divalent group derived from a saturated straight-chain aliphatic hydrocarbon having two to five carbon atoms.

Another object of the present invention to provide an intermediate compound useful to prepare the above 1,3,2-dioxathiolane oxide derivative [I]. This object is achieved by a 1,2-diol derivative [II] and a 1,3-dioxolane derivative [III] represented by the following formulas:



wherein R¹, R², R³, and R⁴ have the same meanings as defined in the above formula [I].



wherein

- R¹, R², R³, and R⁴ have the same meanings as defined in the above formula [I].
- R⁵ and R⁶ may be the same or different and independently mean a hydrogen atom, a lower alkyl group, a substituted or nonsubstituted phenyl group, a lower alkoxy group, or a lower alkylamino group.

In comparison with the conventional epoxy succinic acid derivatives described above, the most important characteristic of the novel 1,3,2-dioxathiolane oxide derivative [I] according to the present invention lies in the fact that a heterocyclic moiety of the derivative is not a substituted epoxy ring but a substituted 1,3,2-dioxathiolane oxide ring. On the basis of this characteristic, the novel compound [I] of the present invention achieves a thiol protease inhibitory effect better than those obtained by conventionally known substances having similar inhibition activity.

Methods of preparing the 1,3,2-dioxathiolane oxide derivative [I] of the present invention will be described below. However, the methods to be described below are merely examples. Therefore, the compound [I] can be prepared by methods other than these exemplified methods. The following methods include methods of preparing the intermediate compounds [II] and [III] of the present invention. As is the

case with the above compound, these intermediate compounds can be prepared by methods other than the exemplified methods.

Preparing method 1

Preparation of 1,3-dioxolane derivative [III]

(Method A)

An amino acid derivative represented by the following formula [IV] or its reactive derivative



(wherein R⁷ represents a protective group of an amino group such as a tert-butoxycarbonyl group and R² has the same meaning as defined above)

and an amine derivative represented by the following formula [V] or its salt are condensed,




(wherein R³ and R⁴ have the same meanings as defined above)

thereby obtaining a compound represented by the following formula [VI]:



(wherein R², R³, R⁴, and R⁷ have the same meanings as defined above.)

Subsequently, the protective group R⁷ of the compound [VI] was removed in accordance with a conventional method to obtain an amide derivative represented by the following formula [VII]:




(wherein R², R³, and R⁴ have the same meanings as defined above.)

Thereafter, this amide derivative [VII] or its reactive derivative and a tartarate monoester derivative synthesized in accordance with a method by A. Tanaka et al. [*Agric. Biol. Chem.*, 48, 2135 (1984)] and represented by the following formula [VIII] or its reactive derivative are condensed,



(wherein R¹, R⁵, and R⁶ have the same meanings as defined above)

thereby obtaining a 1,3-dioxolane derivative represented by the following formula [III]:




(wherein R¹, R², R³, R⁴, R⁵, and R⁶ have the same meanings as defined above.)

(Method B)

A tartarate monoester derivative represented by the above formula [VIII] or its reactive derivative and an amine derivative represented by the following formula [IX] or its salt are condensed,



(wherein R² has the same meaning as defined above) thereby obtaining an amidocarboxylic acid derivative represented by the following formula [X] or its reactive derivative:



(wherein R¹, R², R⁵, and R⁶ have the same meanings as defined above.)


Subsequently, the amidocarboxylic acid derivative [X] or its reactive derivative and an amine derivative represented by the above formula [V] or its salt are condensed, thereby obtaining a 1,3-dioxolane derivative represented by the formula [III].

Preparing method 2

Preparation of 1,2-diol derivative [II]


(Method C)

A 1,2-diol derivative represented by the following formula [II]



(wherein R¹, R², R³, and R⁴ have the same meanings as defined above)

is obtained by subjecting a 1,3-dioxolan derivative represented by the following formula [III] to a reduction process such as catalytic reduction or performing an acid treatment for the derivative:




(wherein R¹, R², R³, R⁴, R⁵, and R⁶ have the same meanings as defined above.)

Preparing method 3

Preparation of 1,3,2-dioxathiolane oxide derivative [I]


(Method D)

Of 1,3,2-dioxathiolane oxide derivatives represented by the formula [I],




(wherein R¹, R², R³, R⁴, and X have the same meanings as defined above)
a 1,3,2-dioxathiolane-2-oxide derivative in which X is -S(O)- can be manufactured as follows.

That is, by applying a method by K.B. Sharpless et al. [*J. Am. Chem. Soc.*, 110, 7538 (1988)] for a 1,2-diol derivative represented by the formula [II],




(wherein R¹, R², R³, and R⁴ have the same meanings as defined above)
a 1,3,2-dioxathiolane-2-oxide derivative represented by the following formula [XI] can be obtained:



(wherein R¹, R², R³, and R⁴ have the same meanings as defined above.)

In addition, by oxidizing this 1,3,2-dioxathiolane 2-oxide derivative [XI], the compound [I] in which X is -S(O)₂-, i.e., a 1,3,2-dioxathiolane-2,2-dioxide derivative represented by the following formula [XII] can be obtained:



(wherein R¹, R², R³, and R⁴ have the same meanings as defined above.)

Note that the compound [II] may be prepared in accordance with the following method.

First, tartaric anhydride is produced from tartaric acid in accordance with a method by M.J. Miller et al., (J. Org. Chem., 47, 4928 (1982)), and R¹OH (wherein R¹ has the same meaning as defined above) is
 5 reacted with the tartaric anhydride without isolating the anhydride, thereby obtaining tartrate monoester represented by the following formula [XIII]:



(wherein R¹ has the same meaning as defined above.)

Subsequently, the monoester [XIII] or its reactive derivative and the above compound [VII] or its salt are
 15 condensed to obtain a 1,2-diol derivative represented by the formula [II].

In the above preparing methods, the starting compounds [V], [VII], and [IX] may be used either in a free state or in the form of a salt. A preferable example of the salt is an acid salt. Examples of the acid salt are an acid salt with an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, or hydrobromic acid, and an acid salt with an organic acid such as trifluoroacetic acid, p-toluenesulfonic acid, tartaric acid,
 20 maleic acid, fumaric acid, or succinic acid.

As reactive derivatives of the compounds [IV], [VIII], and [X], active esters (e.g., N-hydroxysuccinimido ester, pentachlorophenyl ester, N-hydroxybenzotriazole ester) corresponding to the respective compounds, an acid halide (e.g., acid chloride), acid azide, a mixed acid anhydride, and imidazole amide and the like can be used. The active ester may be isolated and subjected to the condensation reaction or subjected to
 25 the condensation reaction in situ without being isolated.

As the protective group (R⁷) in the compounds [IV] and [VI], any protective group normally used in peptide synthesis can be used. Preferable examples of the protective group are a tert-butoxycarbonyl group, a benzyloxycarbonyl group, a benzyl group, a tosyl group, a 2,4-dinitrophenyl group and the like.

Reaction conditions and the like of the respective reactions used in the above preparing methods will be
 30 described in detail below.

(Preparing method 1: Methods A & B)

The condensation reaction between the compound [IV] or its reactive derivative and the compound [V]
 35 or its salt; the condensation reaction between the compound [VII] or its salt and the compound [VIII] or its reactive derivative; the condensation reaction between the compound [IX] or its salt and the compound [VIII] or its reactive derivative; and the condensation reaction between the compound [X] or its reactive derivative and the compound [V] or its salt can be performed in accordance with a known peptide reaction in the presence of a condensation agent.

40 Preferable examples of the condensation agent are dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, phosphorus oxychloride, phosphorus trichloride, thionyl chloride, oxalyl chloride, triphenylphosphine, and a Vilsmeier's reagent.

The condensation reaction is preferably performed at a temperature of -50 °C to 50 °C by preferably selecting dimethylformamide, methylene chloride, dioxane, tetrahydrofuran, acetonitrile, ethyl acetate, pyr-
 45 idine, acetone, and water as a reaction solvent.

In order to perform the condensation reaction by using salts of the compounds [V], [VII], and [IX], the condensation reaction is performed in the presence of a deoxidizer. Examples of the deoxidizer are trialkylamine (e.g., triethylamine and trimethylamine), N,N-dialkylaniline (e.g., N,N-dimethylaniline and N,N-diethylaniline), pyridine, N-alkylmorpholine (e.g., N-methylmorpholine), an alkali metal hydroxide (e.g.,
 50 potassium hydroxide and sodium hydroxide), an alkali metal carbonate (e.g., potassium carbonate), and an alkali metal hydrogen carbonate (e.g., sodium hydrogen carbonate).

Removal of the protective group (R⁷) of the compound [VI] can be easily performed by a conventional method depending on the type of a protective group. For example, catalytic reduction, electrolytic reduction, an acid treatment, an oxidation reaction, or the like may be used.

55

(Preparing method 2: Method C)


The reaction of removing cyclic acetal of the compound [III] to produce the compound [II] can be

performed by using conditions normally used to remove acetal. For example, the reaction can be performed by means of catalytic reduction or using an inorganic acid such as sulfuric acid and hydrochloric acid, an organic acid such as acetic acid and tosyl acid, or a Lewis acid such as boron trichloride.

5 (Preparing method 3: Method D)

The oxidation reaction from the compound [XI] to the compound [XII] can be performed by using a method normally used to perform oxidation from a sulfoxide to a sulfone. For example, a permanganate, a chromate, a peroxide, and a ruthenium trichloride-periodate can be used.

10 A compound represented by formula [I] in which R¹ is a hydrogen atom, i.e., a compound represented by the following formula [XIV] can be easily obtained from a corresponding ester compound [I]:



As a method for this purpose, a method normally performed to convert an ester into a corresponding carboxylic acid, e.g., acid hydrolysis, alkali hydrolysis, or catalytic reduction can be used. A compound represented by formula [XIV] obtained in this manner can be converted into a salt of an alkali metal such as Na or K by a conventional method.

In the above reactions, each of the starting compounds [IV] to [X], the intermediate products [II] and [III], and the target compound [I] have one to four asymmetric carbon atoms. In addition, each of the above reactions can be performed without causing racemization. Therefore, when the starting compounds [IV] to [X] are optically active, their intermediate products and the target compound can also be obtained as optically active compounds. However, the above preparing methods can be performed not using optically active compounds [IV] to [X] but using racemic mixture thereof as starting materials.

A target compound of the present invention represented by formula [I] and prepared by the above methods can form pharmacologically acceptable salts. Examples of the salts are an acid salt with an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, and hydrobromic acid, and an acid salt with an organic acid such as tartaric acid, maleic acid, fumaric acid, succinic acid, and sulfonic acid.

When the 1,3,2-dioxathiolane oxide derivative [I] according to the present invention or its salt is to be used as a medical preparation, the derivative or its salt can be administered to a patient by using a proper administrable form containing the derivative or its salt as an active component and using a proper administration method of either oral or parenteral route. Examples of an orally administrable form are a tablet, a capsule, a granule, a powder, and a liquid preparation. Examples of a parenteral administrable form are an injection preparation, a suppository, an ointment, and a liquid preparation. To obtain these various types of preparations, an excipient, a stabilizer, a preservative agent, a buffer agent, and other additives can be arbitrarily, selectively used in accordance with conventional methods in this field of art. A dose of the preparation is adjustable in accordance with the age, sex, weight, and degree of symptom of a patient and an administration method. Normally, a dose of the compound of the present invention is set from 10 mg to 1 g/day for an adult per day, but it is not limited to this value.

Test examples performed for the novel compound of the present invention to check the inhibitory effect against thiol proteases will be described below.

(Test example I)

(1) CANP inhibition activity in in vitro system

50

A solution mixture consisting of the following components was prepared.

- A 167-mM Tris hydrochloric acid buffer solution (pH = 7.4) (containing 15-mM mercaptoethanol); 40 μ l
 - A solution obtained by dissolving the compound [I] of the present invention in the same Tris hydrochloric acid buffer solution as described above; 40 μ l
 - Purified calpain [obtained by a method described in J. Biol. Chem., 239, 149 (1964)] sampled from a rat brain and dissolved in a 50-mM sodium acetic acid buffer solution (pH = 6.0; containing 1-mM EDTA and 5-mM mercaptoethanol) 11 units/ml; 200 μ l
- 55

- An N,N-dimethylcasein solution (pH = 7.0) (25 mg/ml); 80 μ l

40 μ l of a 167-mM Tris hydrochloric acid buffer solution (pH = 7.4) containing 50-mM CaCl_2 were added to the above solution mixture, and the resultant solution was incubated at 30 °C for 20 minutes. After the incubation, 320 μ l of 10% (W/V) trichloroacetic acid were added to stop the reaction, and the resultant solution was left to stand in an ice bath for one hour. Thereafter, the solution was subjected to centrifugal separation (16,100 \times g, five minutes), and 600 μ l of the supernatant were sampled to measure absorbance (a₁) at 280 nm.

In another step, absorbance (a₂) was obtained by performing an experiment and measurement following the same procedures as described above except that a 167-mM Tris hydrochloric acid buffer solution (pH = 7.4; containing 15-mM mercaptoethanol) was used in place of the 167-mM Tris hydrochloric acid buffer solution containing the compound of the present invention. In addition, absorbance (a₃) was obtained by performing an experiment and measurement following the same procedures as described above except that a 167-mM Tris hydrochloric acid buffer solution (pH = 7.4; containing 1-mM EDTA) was used in place of the 167-mM tris buffer solution (pH = 7.4) containing 50-mM CaCl_2 .

An inhibition ratio was calculated from the above absorbance values (a₁), (a₂), and (a₃) in accordance with the following equation:

$$\text{Inhibition ratio (\%)} = \left[1 - \frac{a_1 - a_3}{a_2 - a_3} \right] \times 100$$

In addition, a concentration (IC₅₀) required for 50% inhibition was calculated by using a semilogarithmic graph. The results are summarized in Table 1 below.

Table 1

Example No. of compound	50% inhibition concentration IC ₅₀ (μ M)
Example 4	15
Example 11	6.0
Example 12	0.3
E-64	7.0

(2) Cathepsin B inhibition activity in in-vitro system

In this experiment, a 100-mM sodium phosphate buffer solution (pH = 6.0; containing 1.33-mM $\text{EDTA} \cdot \text{Na}_2$) was used as all of buffer solutions for solution preparation.

A solution mixture consisting of the following components was prepared.

- The above buffer solution; 850 μ l
- A 20- μ M solution obtained by dissolving the compound of the present invention in the above buffer solution; 50 μ l
- A solution obtained by dissolving cathepsin B (available from Sigma Co.) in the above buffer solution to have a concentration of 0.5 mg/ml; 50 μ l

50 μ l of a 200- μ M solution obtained by dissolving benzoyl-(phenylalanyl-alginy)-4-methylcoumarinamide in the above buffer solution were added to the above solution mixture, and the resultant solution was incubated at 30 °C for 20 minutes.

After the incubation, the reaction solution mixture was cooled in an ice bath to stop the reaction. After 20 minutes elapsed, fluorescence intensity (b₁) at an excitation wavelength of 370 nm and an emission wavelength of 440 nm was measured. At the same time, an experiment was performed using the above buffer solution in place of the solution of cathepsin B in the above system, and fluorescence intensity (b₂) was measured following the same procedures as described above. In addition, an experiment was performed using the above buffer solution in place of the buffer solution of the compound of the present invention, and fluorescence intensity (b₃) was measured following the same procedures as described above.

An inhibition ratio was calculated in accordance with the following equation:

$$\text{Inhibition ratio (\%)} = \left[1 - \frac{b_1 - b_2}{b_3 - b_2} \right] \times 100$$

- 5 and a concentration (IC_{50}) required for 50% inhibition was calculated by using a semilogarithmical graph. The results are summarized in Table 2 below.

Table 2

10	Example No. of compound	50% inhibition concentration IC_{50} (μM)
	Example 4	0.025
	Example 11	0.009
15	Example 12	0.0007
	Example 14	0.015
	Example 16	0.003
20	E-64	0.035

(Test example II)

- 25 The following test was performed to confirm that the compound of the present invention had no adverse effect on activity of a proteolytic enzyme such as trypsin, chymotrypsin, elastase, and leucine-aminopeptidase.

(1) Effect on trypsin

- 30 In this experiment, a 50-mM Tris hydrochloric acid buffer solution ($pH = 8.0$) was used as all of buffer solutions for solution preparation.

A solution mixture consisting of the following components was prepared.

- The above buffer solution; 850 μl
- 35 • A 20- μM solution obtained by dissolving the compound of the present invention in the above buffer solution; 50 μl
- A solution obtained by dissolving trypsin (available from Sigma Co.) in the above buffer solution to have a concentration of 0.5 mg/ml; 50 μl

- 40 50 μl of a 200- μM solution obtained by dissolving 7-(prolyl-phenylalanyl-alginy)-4-methyl-coumarinamide in the above buffer solution was added to the above solution mixture, and the resultant solution was incubated at 30°C for 20 minutes.

- After the incubation, the reaction solution mixture was poured in an ice bath to stop the reaction. After 20 minutes elapsed, fluorescence intensity (c_1) at an excitation wavelength of 370 nm and an emission wavelength of 440 nm was measured. At the same time, experiments were performed using the above buffer solution in place of the trypsin solution and in place of the buffer solution of the compound of the present invention in the above system, thereby measuring fluorescence intensities (c_2) and (c_3) following the same procedures as described above, respectively.

When an inhibition ratio was calculated in accordance with the following equation, the inhibition ratio was 0%:

$$\text{Inhibition ratio (\%)} = \left[1 - \frac{c_1 - c_2}{c_3 - c_2} \right] \times 100$$

- 55 This result indicates that each compound of the present invention described in Table 2 does not inhibit trypsin under the above conditions.

Similarly, when a test was performed to check inhibition activity of the compound of the present invention against chymotrypsin, elastase, and leucine-aminopeptidase, an inhibition ratio for each enzyme

was 0%.

[Best Mode of Carrying Out the Invention]

The present invention will be described in more detail below by way of its references examples and working examples, but the present invention is not limited to these examples. For example, the following compounds also belong to the present invention.


- o Ethyl (4S,5S)-5-[(S)-1-decylcarbamoyl-3-methylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2-oxide
- o Ethyl (4S,5S)-5-[(S)-1-cyclopropylcarbamoyl-3-methylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide
- o Ethyl (4S,5S)-5-[(S)-1-cyclopentylcarbamoyl-3-methylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2-oxide
- o Ethyl (4S,5S)-5-[(S)-1-cyclopentylcarbamoyl-3-methylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide
- o Ethyl (4S,5S)-5-[(S)-1-(4-guanidobutylcarbamoyl)-3-methylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide
- o Ethyl (4S,5S)-5-[(S)-3-methyl-1-(N,N-dimethylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide
- o Ethyl (4S,5S)-5-[(S)-1-(N,N-diisopropylcarbamoyl)-3-methylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2-oxide
- o Ethyl (4S,5S)-5-[(S)-1-(N,N-diisopropylcarbamoyl)-3-methylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide
- o Ethyl (4S,5S)-5-[(S)-3-methyl-1-(pyrrolidine-1-yl-carbonyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide
- o Ethyl (4S,5S)-5-[(S)-2-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2-oxide
- o Ethyl (4S,5S)-5-[(S)-2-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide
- o Ethyl (4S,5S)-5-[(S)-1-(3-methylbutylcarbamoyl)methylthiopropylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide
- o (4S,5S)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxy-2-oxide
- o Potassium (4S,5S)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide
- o Butyl (4S,5S)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide

Abbreviations used in the description of examples to be presented below represent the following meanings.

NMR	nuclear magnetic resonance spectrum (¹ H-NMR)
IR	infrared absorption spectrum
SIMS	secondary ion mass analysis spectrum
Boc	tert-butoxycarbonyl group
Bu ^t	tert-butyl group
Et	ethyl group
mp	melting point

Reference Example 1

Boc-L-leucylisoamylamide




Boc-L-leucine-succinimide ester (7.00 g) and isoamylamine (1.80 g) were mixed in 1,2-dimethoxyethane (70 ml) under ice cooling, and the resultant mixture was stirred at room temperature for three hours. A proper amount of a 2.5% aqueous sodium carbonate solution was added to the reaction solution, and extraction was performed three times using ethyl acetate. The organic layer was washed with saturated sodium chloride solution and dried with magnesium sulfate, and the solvent was distilled off under a reduced pressure. As a result, 6.40 g of a target compound were obtained. NMR data of the product was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.89 - 0.95 (12 H, m, -CH₃ × 4),
 1.35 - 1.55 (9 H, m),
 1.55 - 1.80 (6 H, m),
 3.27 (2 H, q, J = 6.9 Hz, -CONHCH₂-),
 4.03 (1 H, m, >CHCONH-),
 4.89 (1 H, br s, -NH-Boc),
 6.12 (1 H, br s, -CONHCH₂-)

Reference Example 2

L-leucylisoamylamide*hydrobromide




Boc-L-leucylisoamylamide (6.20 g) obtained in Reference Example 1 was dissolved in acetic acid (20 ml), and a 25% hydrobromic acid/acetic acid solution (50 ml) was added to the resultant solution under ice cooling. Thereafter, the solution mixture was stirred at room temperature for 30 minutes, and the reaction solution was subjected to distillation under a reduced pressure. The obtained yellow viscous oily substance was washed with petroleum ether and ether. As a result, 5.86 g of a target compound were obtained as a yellowish white powder. NMR data of the compound was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.89 - 1.10 (12H, m, -CH₃ × 4),
 1.46 (2 H, q, J = 6.9 Hz, -NHCH₂CH₂-),
 1.60 - 2.00 (4H, m),
 3.17 (1 H, br s, -NHCH₂-),
 3.40 (1 H, br s, -NHCH₂-),
 4.22 (1 H, br s, >CHCONH-),
 4.39 (1 H, br s, -CONHCH₂-),
 8.01 (2 H, br s, -NH₂)

Reference Example 3

L-leucyldibutylamide



Following the same procedures as in Reference Examples 1 and 2, L-leucyldibutylamide*hydrobromide obtained from Boc-L-leucine-succinimide ester (1.50 g) and dibutylamine (553 mg) was treated by saturated

sodium bicarbonate aqueous solution to obtain 871 mg of a target compound. NMR data of the compound was as follows.


¹H-NMR (CDCl₃)

5 δ ppm: 0.88 - 1.06 (12 H, m, -CH₃ × 4),
 1.28 - 1.93 (11 H, m),
 3.12 (2 H, m, >N-CH₂-),
 3.29 (1 H, m, >N-CH₂-),
 3.57 (2 H, m, >N-CH₂-, >CHCON<)

10 Reference Example 4

L-leucylbenzylamide

15



20

Following the same procedures as in Reference Examples 1, 2, and 3, 917 mg of a target compound were obtained from Boc-L-leucine-succinimide ester (1.52 g) and benzylamine (497 mg). NMR data of the compound was as follows.


25 ¹H-NMR (CDCl₃)

30 δ ppm: 0.84 - 1.08 (6 H, m, -CH₃ × 2),
 1.30 - 1.83 (3 H, m),
 3.43 (1 H, dd, J = 2.9, 9.7 Hz, >CHCONH-),
 4.44 (2 H, d, J = 5.9 Hz, Ph-CH₂-),
 7.30 (5 H, m, arom)

Reference Example 5

L-leucylpiperidylamide

35



40

45 Following the same procedures as in Reference Examples 1, 2, and 3, 386 mg of a target compound were obtained from Boc-L-leucine-succinimide ester (1.61 g) and piperidine (420 mg). NMR data of the compound was as follows.


¹H-NMR (CDCl₃)

50 δ ppm: 0.86 - 1.02 (6 H, m, -CH₃ × 2),
 1.22 - 1.92 (9 H, m),
 3.40 (2 H, m),
 3.57 (2 H, m),
 3.79 (1 H, m, >CHCON<)

Reference Example 6

55

L-leucyldecylamide



5

Following the same procedures as in Reference Examples 1, 2, and 3, 1.17 g of a target compound were obtained from Boc-L-leucine-succinimide ester (1.53 g) and decylamine (731 mg). NMR data of the compound was as follows.

¹H-NMR (CDCl₃)


δ ppm: 0.81 - 1.05 (9 H, m, -CH₃ × 3),
1.18 - 1.82 (19 H, m),
3.22 (2 H, q, J = 7.0 Hz, -CONHCH₂-),
3.37 (1 H, dd, J = 3.6, 9.8 Hz, >CHCONH-)

15

Reference Example 7

L-leucylcyclohexylamide

20



25

Following the same procedures as in Reference Examples 1, 2, and 3, 430 mg of a target compound were obtained from Boc-L-leucine-succinimide ester (1.06 g) and cyclohexylamine (320 mg). NMR data of the compound was as follows.

¹H-NMR (CDCl₃)


δ ppm: 0.89 - 1.03 (6 H, m, -CH₃ × 2),
1.08 - 1.95 (13 H, m),
3.34 (1 H, m, -CONHCH<),
3.74 (1 H, m, >CHCONH<),
7.11 (1 H, br, s)

35

Reference Example 8

L-phenylalanylisoomylamide

40



45

50

Following the same procedures as in Reference Examples 1, 2, and 3, 709 mg of a target compound were obtained from Boc-1-phenylalanine-succinimide ester (2.52 g) and isoamylamine (666 mg). NMR data of the compound was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.82 - 1.01 (6 H, m, -CH₃ × 2),
1.31 - 1.45 (2 H, m),
1.51 - 1.67 (2 H, m),

55


2.69 (1 H, dd, J = 9.3, 13.7 Hz),
 3.21 - 3.36 (3 H, m),
 3.59 (1 H, dd, J = 4.1, 9.3 Hz),
 7.16 - 7.39 (6 H, m, arom, -CONH-),

5

Reference Example 9

L-norleucylisoamylamide

10



15

Following the same procedures as in Reference Examples 1, 2, and 3, 874 mg of a target compound were obtained from Boc-L-norleucine-succinimide ester (2.62 g) and isoamylamine (763 mg). NMR data of the compound was as follows.

¹H-NMR (CDCl₃)

20


δ ppm: 0.76 - 1.03 (9 H, m, -CH₃ × 3),
 1.20 - 1.92 (9 H, m),
 3.18 - 3.39 (3 H, m),
 7.22 (1 H, br s)

25

Reference Example 10

Monobenzyl D-tartrate ester

30



35

A target compound was synthesized in accordance with a method by M.J. Miller et al. [*J. Org. Chem.*, 47, 4928 (1982)].

Dicyclohexylcarbodiimide (4.94 g) was added under ice cooling to a solution prepared by dissolving D-tartaric acid (3.00 g) in anhydrous tetrahydrofuran (40 ml), and the resultant solution was stirred under ice cooling. Thereafter, the solution was stirred for five hours while the temperature was gradually raised to room temperature, and the produced dicyclohexyl urea was removed. Benzyl alcohol (4.12 ml) was added to the reaction filtrate, and the resultant solution was stirred at room temperature overnight. The reaction solution was condensed under a reduced pressure, ethyl acetate (50 ml) was added to dissolve the reaction product, and extraction was performed using a 10% sodium carbonate solution. The extracted aqueous solution was adjusted to about pH 2, and then was extracted again by ethyl acetate. The extracted organic layer was washed with saturated sodium chloride solution and dried with magnesium sulfate, and the solvent was distilled off under a reduced pressure to obtain a crude product. This crude product was recrystallized from chloroform to obtain 402 mg of a target compound. NMR data of the compound was as follows.

¹H-NMR (CDCl₃)

50

δ ppm: 4.64 (2 H, d),
 5.26 (2 H, br s, -CH₂Ph),
 7.34 (5 H, br s, arom)

55

Reference Example 11

(1S,2S)-2-benzylloxycarbonyl-1,2-dihydroxyethanecarbonyl-L-leucine


Benzyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-tert-butoxycarbonylbutylcarbamoyl]propionate was prepared from monobenzyl D-tartrate ester obtained in Reference Example 10 and leucine tert-butylester* hydrochloride by using dicyclohexylcarbodiimide and N-hydroxysuccinimide. This product (2.21 g) was dissolved in 20 ml of 4-N hydrochloric acid/dioxane, and the resultant solution was stirred under ice cooling while the temperature was gradually returned to room temperature, thereby obtaining 1.31 g of a target compound. NMR data of the compound was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.89 - 1.09 (6 H, m, -CH₃ × 2),
 1.62 - 1.90 (3 H, m, -CH₂CH(CH₃)₂),
 4.48 (1 H, d, J = 2.0 Hz),
 4.54 (1 H, m, >CHCONH-),
 4.59 (1 H, d, J = 2.0 Hz),
 5.19 (1 H, d, J = 13.6 Hz, -CH₂Ph),
 5.29 (1 H, d, J = 13.6 Hz, -CH₂Ph),
 7.30 - 7.50 (5H, m, arom)

Example 1

Ethyl (4S,5S)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-2-phenyl-1,3-dioxolane-4-carboxylate



L-leucylisoamylamide*hydrobromide (1.90 g) obtained in Reference Example 2 was dissolved in dimethylformamide (40 ml). Triethylamine (1.35 ml) and diethyl cyanophosphonate (1.63 g) were sequentially added to the resultant solution under ice cooling, and the solution was stirred under ice cooling. A dimethylformamide (20 ml) solution of 2,3-O-benzylidene-ethyltartrate monoester [A. Tanaka et al. Agric. Biol. Chem., 48, 2135 (1984)] (2.20 g) was added to the resultant solution under ice cooling, and the solution was stirred under ice cooling and then stirred at 4°C overnight. The reaction solution was condensed to be about 30 ml under a reduced pressure, and 150 ml of an ethyl acetate/benzene solution mixture were added to the condensed solution. The organic layer was sequentially washed with 10% citric acid, water, saturated sodium bicarbonate solution, water, and saturated sodium chloride solution and dried with magnesium sulfate. The solvent was distilled off from the dried organic layer under a reduced pressure to obtain a crude product. This crude product was purified by using a silica gel column chromatography (a developing solvent; hexane : ethyl acetate = 2 : 1) to obtain 2.22 g of a target compound in a form of white crystals. NMR data and SIMS data of the compound were as follows.

¹H-NMR (CDCl₃)


δ ppm: 0.84 - 1.00 (12 H, m, -CH₃ × 4),
 1.30 - 1.48 (5 H, m),
 1.48 - 1.75 (4 H, m),
 3.24 (2 H, m, -NHCH₂-),
 4.20 - 4.50 (3 H, m),
 4.78 (1/2 H, d, J = 3.1 Hz),
 4.91 (1/2 H, d, J = 3.5 Hz),
 4.93 (1/2 H, d, J = 3.5 Hz),
 5.02 (1/2 H, d, J = 3.1 Hz),

6.00 (1/2 H, s, Ph-CH<),
 6.02 (1 H, br s, -CONHCH₂-),
 6.21 (1/2 H, s, Ph-CH<),
 6.78 (1/2 H, d, J = 8.9 Hz, -NHCHCO-),
 7.04 (1/2 H, d, J = 8.9 Hz, -NHCHCO-),
 7.40 - 7.56 (5 H, m, arom.)

SIMS m/z; 449 (M + 1)

Example 2

Ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]propionate




Ethyl (4S,5S)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-2-phenyl-1,3-dioxolane-4-carboxylate (2.07 g) obtained in Example 1 was dissolved in acetic acid (40 ml). Palladium black (0.40 g) was added to the resultant solution, and the solution was strongly stirred at room temperature for 60 hours under a hydrogen flow at 4.1 atm. After the catalyst was filtered off, the filtrate was condensed under a reduced pressure to obtain a crude product. The crude product was purified by using a silica gel column chromatography (a developing solvent; hexane : ethyl acetate = 1 : 1 → 1 : 3) to obtain 1.38 g of a target compound. NMR data of the compound was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.89 - 0.95 (12 H, m, -CH₃ × 4),
 1.30 (3 H, t, J = 7.1 Hz, -OCH₂CH₃),
 1.33 - 1.45 (2 H, m),
 1.50 - 1.72 (4 H, m),
 3.24 (2 H, m, -NHCH₂-),
 3.52 (1 H, br s),
 4.28 (2 H, q, J = 7.1 Hz, -COCH₂CH₃),
 4.45 (1 H, m, >CHCONH-),
 4.49 (1 H, br s),
 4.66 (1 H, br s),
 4.91 (1 H, br s),
 6.57 (1 H, t, J = 4.4 Hz, -CONHCH₂-),
 7.33 (1 H, d, J = 8.6 Hz, -NHCHCO-)

Example 3

Ethyl (4S,5S)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2-oxide



Ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]propionate (305 mg) obtained in Example 2 was dissolved in carbon tetrachloride (6 ml). Thionyl chloride (69 μ l) was added to the resultant solution at room temperature, and the solution was heated under reflux for 40 minutes. The reaction solution was condensed under a reduced pressure to obtain a crude product. This crude product was purified by using a silica gel column chromatography (a developing solvent; hexane : ethyl acetate = 2 : 1) to obtain 174 mg of a target compound as white crystals. This product was a diastereomer mixture due to 2-position asymmetry. Therefore, the mixture was subjected to the silica gel column chromatography again to obtain a high-polarity isomer (compound A) and a low-polarity isomer (compound B). NMR data and SIMS data of the compounds A and B were as follows.

Compound A

¹H-NMR (CDCl₃)

δ ppm: 0.89 - 0.95 (12 H, m, -CH₃ \times 4),
 1.34 (3 H, t, J = 7.1 Hz, -OCH₂CH₃),
 1.36 - 1.50 (2 H, m),
 1.50 - 1.70 (4 H, m),
 3.26 (2 H, m, -NHCH₂-),
 4.33 (2 H, q, J = 7.1 Hz, -OCH₂CH₃),
 4.35 - 4.40 (1 H, m, >CHCONH),
 5.22 (1 H, d, J = 3.7 Hz),
 5.66 (1 H, d, J = 3.7 Hz),
 5.93 (1 H, br s, -CONHCH₂-),
 6.94 (1 H, d, J = 8.0 Hz, -NHCHCO-)

SIMS m/z; 407 (M + 1)

Compound B


¹H-NMR (CDCl₃)

δ ppm: 0.89 - 0.95 (12 H, m, -CH₃ \times 4),
 1.34 (3 H, t, J = 7.1 Hz, -OCH₂CH₃),
 1.36 - 1.50 (2 H, m),
 1.50 - 1.70 (4 H, m),
 3.27 (2 H, m, -NHCH₂-),
 4.33 (2 H, q, J = 7.1 Hz, -OCH₂CH₃),
 4.35 - 4.40 (1 H, m, >CHCONH),
 5.38 (1 H, d, J = 4.0 Hz),
 5.72 (1 H, d, J = 4.0 Hz),
 5.90 (1 H, br s, -CONHCH₂-),
 6.97 (1 H, d, J = 8.0 Hz, -NHCHCO-)

SIMS m/z; 407 (M + 1)

Example 4

Ethyl (4S,5S)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-

2,2-dioxide

Following the same procedures as in Example 3, ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]propionate (200 mg) was converted into ethyl-(4S,5S)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl) butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2-oxide. Acetonitrile (3 ml) was added to the reaction solution (carbon tetrachloride; 3 ml) without isolating nor purifying the product, and the resultant solution was stirred at room temperature. Subsequently, a solution prepared by dissolving sodium periodate (252 mg) and ruthenium trichloride hydrate (catalytic amount) in water (4.5 ml) was added, and the resultant solution was stirred at room temperature for 20 hours. Diethylether was added to the reaction solution, and the ether layer of the solution was sequentially washed with water, saturated sodium bicarbonate solution, and saturated sodium chloride solution. The resultant layer was dried with magnesium sulfate, and the solvent was distilled off under a reduced pressure to obtain a crude product. This crude product was purified by using a silica gel column chromatography (a developing solvent; hexane : ethyl acetate = 2 : 1) to obtain 117 mg of a target compound as a white powder. NMR data, IR data, and SIMS data of the compound were as follows.

¹H-NMR (CDCl₃)


δ ppm: 0.89 - 0.96 (12 H, m, -CH₃ × 4),
 1.36 (3 H, t, J = 7.2 Hz, -OCH₂CH₃),
 1.35 - 1.50 (2 H, m),
 1.50 - 1.73 (4 H, m),
 3.30 (2 H, m, -NHCH₂-),
 4.37 (2 H, q, J = 7.2 Hz, -OCH₂CH₃),
 4.50 (1 H, m, >CHCONH-),
 5.51 (1 H, d, J = 4.0 Hz),
 5.53 (1 H, d, J = 4.0 Hz),
 6.28 (1 H, t, J = 4.9 Hz, -CONHCH₂-),
 7.47 (1 H, d, J = 8.0 Hz, -NHCHCO-)

IR $\nu_{\text{max}}^{\text{CHCl}_3}$ cm⁻¹: 1750, 1677, 1413, 1229

SIMS m/z; 423 (M + 1)

Example 5

Ethyl (4R,5R)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-2-phenyl-1,3-dioxolane-4-carbox-
ylate




15 Following the same procedures as in Example 1, 3.38 g of a target compound were obtained from L-leucylisoamylamide*hydrobromide (2.50 g) obtained in Reference Example 2 and 2,3-O-benzylidene-L-monoethylester tartarate (3.00 g). NMR data of the compound was as follows.

¹H-NMR (CDCl₃)

20 δ ppm: 0.88 - 0.97 (12 H, m, -CH₃ × 4),
 1.30 - 1.50 (5 H, m),
 1.50 - 1.70 (4 H, m),
 3.27 (2 H, m, -NHCH₂-),
 4.30 - 4.50 (3H, m, -OCH₂CH₃, >CHCONH-),
 4.79 (1/2 H, d, J = 3.5 Hz),
 25 4.88 (1/2 H, d, J = 4.4 Hz),
 4.92 (1/2 H, d, J = 4.4 Hz),
 4.94 (1/2 H, d, J = 3.5 Hz),
 5.97 (1 H, br s, -CONHCH₂-),
 6.00 (1/2 H, s, Ph-CH<),
 30 6.17 (1/2 H, s, Ph-CH<),
 6.85 (1/2 H, d, J = 8.6 Hz, -NHCHCO-),
 7.12 (1/2 H, d, J = 8.6 Hz, -NHCHCO-),
 7.40 - 7.60 (5 H, m, arom.)

35 Example 6

Ethyl (2R,3R)-2,3-dihydroxy-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]propionate



50 Following the same procedures as in Example 2, 654 mg of a target compound were prepared from ethyl (4R,5R)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-2-phenyl-1,3-dioxolane-4-carboxylate (1.00 g) obtained in Example 5. NMR data of the compound was as follows.


¹H-NMR (CDCl₃)

55 δ ppm: 0.86 - 0.96 (12 H, m, -CH₃ × 4),
 1.31 - 1.45 (5 H, m),
 1.50 - 1.75 (4 H, m),
 3.20 (2 H, m, -NHCH₂-),
 4.27 (2 H, m, -OCH₂CH₃),
 4.47 (1 H, m, >CHCONH-),

4.55 (1 H, br s),
 4.68 (1 H, br s),
 5.35 (1 H, br s),
 6.99 (1 H, t, J = 4.9 Hz, -CONHCH₂-),
 7.61 (1 H, d, J = 8.5 Hz, -NHCHCO-)

Example 7

Ethyl (4R,5R)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-
 2-oxide



Following the same procedures as in Example 3, 28 mg of a target compound were prepared from ethyl (2R,3R)-2,3-dihydroxy-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]propionate (150 mg) obtained in Example 6. This compound was a diastereomer mixture due to 2-position asymmetry. Therefore, the compound was subjected to a silica gel column chromatography to obtain a high-polarity isomer (compound C) and a low-polarity isomer (compound D). NMR data of the compounds C and D were as follows.

High-polarity isomer (C)

¹H-NMR (CDCl₃)

δ ppm: 0.86 - 0.97 (12 H, m, -CH₃ × 4),
 1.30 - 1.50 (5 H, m),
 1.50 - 1.93 (4 H, m),
 3.20 (2 H, m, -NHCH₂-),
 4.33 (2 H, q, J = 7.1 Hz, -OCH₂CH₃),
 4.40 - 4.55 (1 H, m, >CHCONH-),
 5.36 (1 H, d, J = 2.7 Hz),
 5.84 (1 H, d, J = 2.7 Hz),
 6.45 (1 H, br s, -CONHCH₂-),
 6.66 (1 H, d, J = 8.8 Hz)


Low-polarity isomer (D)

¹H-NMR (CDCl₃)

δ ppm: 0.89 - 0.95 (12 H, m, -CH₃ × 4),
 1.30 - 1.50 (5 H, m),
 1.50 - 1.93 (4 H, m),
 3.22 (2 H, m, -NHCH₂-),
 4.32 (2 H, q, J = 7.1 Hz, -OCH₂CH₃),
 4.38 - 4.45 (1 H, m, >CHCONH-),
 5.33 (1 H, d, J = 4.4 Hz),
 5.72 (1 H, d, J = 4.4 Hz),
 6.10 (1 H, br s, -CONHCH₂-),
 7.18 (1 H, d, J = 8.5 Hz)

Example 8

Ethyl (4R,5R)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolano-4-carboxylate-2,2-dioxide




Following the same procedures as in Example 3, ethyl (4R,5R)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2-oxide was prepared from ethyl (2R,3R)-2,3-dihydroxy-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]propionate (40 mg). Subsequently, 30 mg of a target compound were obtained following the same procedures as in Example 4. NMR data of the compound was as follows.

¹H-NMR (CDCl₃)

δ ppm : 0.89 - 0.97 (12 H, m, -CH₃ × 4),
 1.30 - 1.50 (5 H, m),
 1.50 - 1.90 (4 H, m),
 3.25 (2 H, m, -NHCH₂-),
 4.38 (2 H, q, J = 7.2 Hz, -OCH₂CH₃),
 4.50 (1 H, m, >CHCONH-),
 5.51 (1 H, d, J = 4.1 Hz),
 5.53 (1 H, d, J = 4.1 Hz),
 6.10 (1 H, br s, -CONHCH₂-),
 7.18 (1 H, d, J = 8.5 Hz, -NHCHCO-)

Example 9

(2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]propionic acid




Ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]propionate (309 mg) obtained in Example 2 was dissolved in methanol. 2N KOH (472 μl) was added to the resultant solution, and the solution was stirred at 0 °C for two hours. Thereafter, the solvent was distilled off under a reduced pressure, sodium bicarbonate solution was added to adjust a pH to be about 8, and the aqueous layer was washed with ethyl acetate. Subsequently, the pH was adjusted to about 2 by dilute hydrochloric acid, sodium chloride was added until the solution was saturated, and the aqueous layer was extracted by ethyl acetate. The extracted organic layer was washed with sodium chloride solution and dried with magnesium sulfate, and the solvent was distilled off under a reduced pressure, thereby obtaining 264 mg of a target compound. NMR data of the compound was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.80 - 1.06 (12 H, m, -CH₃ × 4),
 1.30 - 1.47 (2 H, m),
 1.53 - 1.75 (4 H, m),
 3.11 (1 H, m, -NHCH₂-),
 3.31 (1 H, m, -NHCH₂-),
 4.50 (1 H, m, >CHCONH-),
 4.56 (1 H, br s),
 4.62 (1 H, br s),
 7.25 (1 H, br s),
 7.88 (1 H, br s)

Example 10

Benzyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]propionate




(2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]propionic acid (1.40 g) obtained in Example 9 and sodium bicarbonate (712 mg) were suspended in dimethylformamide (20 ml). A dimethylformamide (20 ml) solution of benzyl bromide (3.56 g) was added to the resultant suspension, and the suspension was stirred at room temperature for 24 hours. Water was added after the reaction, and then was extracted by ethyl acetate. The organic layer was sequentially washed with water and saturated sodium chloride solution. After the resultant layer was dried with magnesium sulfate, the solvent was distilled off under a reduced pressure to obtain a crude product. This crude product was purified by using a silica gel column chromatography (a developing solvent; hexane : ethyl acetate = 1 : 1 → 1 : 3) to obtain 1.13 g of a target compound. NMR data of the compound was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.78 - 1.03 (12 H, m, -CH₃ × 4),
 1.28 - 1.40 (2 H, m),
 1.48 - 1.72 (4 H, m),
 3.18 (2 H, m, -NHCH₂-),
 3.61 (1 H, d, J = 7.7 Hz, -OH),
 4.47 (1 H, m, >CHCONH-),
 4.52 (1 H, dd, J = 7.2, 1.8 Hz),
 4.71 (1 H, dd, J = 7.7, 1.9 Hz),
 5.12 - 5.31 (3 H, m, Ph-CH₂-, -OH),
 6.70 (1 H, t, J = 5.9 Hz, -CONHCH₂-),
 7.34 (1 H, m, arom),
 7.40 (1 H, d, J = 8.7 Hz, -NHCHCO-)

Example 11

Benzyl (4S,5S)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide



Following the same procedures as in Example 4, 981 mg of a target compound were prepared from benzyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]propionate (1.70 g) obtained in Example 10. NMR data and SIMS data of the compound were as follows.


¹H-NMR (CDCl₃)

δ ppm: 0.80 - 1.05 (12 H, m, -CH₃ × 4),
 1.35 - 1.50 (2 H, m),
 1.55 - 1.71 (4 H, m),
 3.28 (2 H, m, -NHCH₂-),
 4.47 (1 H, m, >CHC(=O)NH-),
 5.31 (2 H, s, Ph-CH₂-),
 5.47 (1 H, d, J = 3.7 Hz),
 5.54 (1 H, d, J = 3.7 Hz),
 5.91 (1 H, br s, -CONHCH₂-),
 7.11 (1 H, d, J = 8.2 Hz, -NHCHC(=O)-),
 7.37 (1 H, s, arom)

SIMS m/z: 485 (M + 1)

Example 12

(4S,5S)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxy-2,2-dioxide



Benzyl (4S,5S)-5-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide (1.07 g) obtained in Example 11 was dissolved in tetrahydrofuran (65 ml), 10% palladium carbon (110 mg) was added to the resultant solution, and the solution was stirred at room temperature for four hours under a hydrogen flow. After the catalyst was filtered out, the resultant filtrate was condensed under a reduced pressure to obtain 1.05 g of a target compound. NMR data, IR data, and SIMS data of the compound were as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.82 - 1.03 (12 H, m, -CH₃ × 4),
 1.35 - 1.46 (2 H, m),
 1.50 - 1.79 (4 H, m),
 3.11 - 3.41 (2 H, m, -NHCH₂-),

4.49 (1 H, m, >CHCONH-),
 5.51 (2 H, m),
 6.63 (1 H, br s, $\text{-CONHCH}_2\text{-}$),
 7.72 (1 H, d, $J = 8.3 \text{ Hz}$, -NHCHCO-)

5

IR $\nu_{\text{max}}^{\text{CHCl}_3} \text{ cm}^{-1}$: 1749, 1689, 1637, 1528, 1413, 1213


SIMS m/z : 395 ($M + 1$)

10

Example 13

Ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-1-(N,N-dibutylcarbamoyl)-3-methylbutylcarbamoyl]propionate

15



20

25 L-leucyldibutylamide obtained in Reference Example 3 was reacted following the same procedures as in Example 1. Subsequently, 1.05 g of a target compound were prepared from the obtained compound following the same procedures as in Example 2. NMR data of the target compound was as follows.

$^1\text{H-NMR}$ (CDCl_3)


δ ppm: 0.83 - 1.09 (12 H, m, $\text{-CH}_3 \times 4$),
 1.22 - 1.81 (14 H, m),
 3.10 (1 H, m, $\text{>N-CH}_2\text{-}$),
 3.30 (2 H, t, $J = 8.0 \text{ Hz}$, $\text{>N-CH}_2\text{-}$),
 3.42 - 3.61 (2 H, m, $\text{>N-CH}_2\text{-}$, -OH),
 4.31 (2 H, m, $\text{-OCH}_2\text{CH}_3$),
 4.51 (1 H, dd, $J = 1.8, 7.2 \text{ Hz}$),
 4.68 (1 H, dd, $J = 1.8, 7.4 \text{ Hz}$),
 4.89 (1 H, d, $J = 7.2 \text{ Hz}$, -OH),
 4.99 (1 H, m, >CHCON<),
 7.44 (1 H, d, $J = 9.0 \text{ Hz}$, -NHCHCO-)

40

Example 14

Ethyl (4S,5S)-5-[(S)-1-(N,N-dibutylcarbamoyl)-3-methylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide

45



55

Following the same procedures as in Example 4, 53 mg of a target compound were prepared as a

colorless transparent oily product from ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-1-(N,N-dibutylcarbamoyl)-3-methylbutylcarbamoyl]propionate (188 mg) obtained in Example 13. NMR data and SIMS data of the target compound were as follows.


¹H-NMR (CDCl₃)

5	δ ppm:	0.88 - 1.07 (12 H, m, $-\text{CH}_3 \times 4$), 1.36 (3 H, t, $J = 7.1$ Hz, $-\text{OCH}_2\text{CH}_3$), 1.25 - 1.72 (11 H, m), 3.07 (1 H, m, $>\text{N}-\text{CH}_2-$), 3.26 (2 H, m, $>\text{N}-\text{CH}_2-$),
10		3.56 (1 H, m, $>\text{N}-\text{CH}_2-$), 4.36 (2 H, q, $J = 7.1$ Hz, $-\text{OCH}_2\text{CH}_3$), 4.96 (1 H, m, $>\text{CHCON}<$), 5.47 (1 H, d, $J = 4.0$ Hz), 5.52 (1 H, d, $J = 4.0$ Hz),
15		7.32 (1 H, d, $J = 8.8$ Hz, $-\text{NHCHCO}-$)

SIMS m/z : 465 ($M + 1$)

Example 15

20 Ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-1-benzylcarbamoyl-3-methylbutylcarbamoyl]propionate




L-leucylbenzylamide obtained in Reference Example 4 was reacted following the same procedures as in Example 1, and the obtained compound was reacted following the same procedures as in Example 2, thereby obtaining 986 mg of a target compound. NMR data of the target compound was as follows.

35 $^1\text{H-NMR}$ (CDCl_3)

δ ppm: 0.78 - 1.00 (6 H, m, $-\text{CH}_3 \times 2$),
1.23 (3 H, t, $J = 7.1$ Hz, $-\text{OCH}_2\text{CH}_3$),
1.51 - 1.70 (3 H, m),
3.67 (1 H, d, $J = 7.2$ Hz, $-\text{OH}$),
4.08 - 4.21 (3 H, m),
4.33 - 4.46 (2 H, m),
4.51 - 4.67 (2 H, m),
5.47 (1 H, d, $J = 6.4$ Hz, $-\text{OH}$),
7.11 - 7.34 (5 H, m, arom),
7.53 (1 H, d, $J = 8.6$ Hz, $-\text{NHCHCO}-$),
7.64 (1 H, t, $J = 5.6$ Hz, $-\text{CONHCH}_2-$)

Example 16

50 Ethyl (4S,5S)-5-[(S)-1-benzylcarbamoyl-3-methylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-diox-
ide



Following the same procedures as in Example 4, 363 mg of a target compound were prepared as white crystals from ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-1-benzylcarbamoyl-3-methylbutylcarbamoyl]propionate (473 mg) obtained in Example 15. NMR data, IR data, SIMS data, and a melting point of the target compound were as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.93 (6 H, t, J = 5.9 Hz, -CH₃ × 2),
 1.36 (3 H, t, J = 7.2 Hz, -OCH₂CH₃),
 1.58 - 1.72 (3 H, m),
 4.32 - 4.55 (5 H, m, -OCH₂CH₃, Ph-CH₂-, >CHCONH-),
 5.45 (2 H, dd, J = 3.8, 8.7 Hz),
 6.29 (1 H, t, J = 4.8 Hz, -CONHCH₂-),
 7.04 (1 H, d, J = 8.2 Hz, -NHCHCO-),
 7.21 - 7.40 (5 H, m, arom)


IR ν_{max} 3 cm⁻¹: 1750, 1678, 1522, 1413, 1216,

SIMS m/z; 443 (M + 1)

mp; 141.0 - 142.0 °C

Example 17

Ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-(piperidine-1-ylcarbonyl)butylcarbamoyl]propionate



L-leucylpiperidylamide obtained in Reference Example 5 was reacted following the same procedures as in Example 1, and the obtained compound was reacted following the same procedures as in Example 2, thereby obtaining 512 mg of a target compound. NMR data of the target compound was as follows.


¹H-NMR (CDCl₃)

δ ppm: 0.85 - 1.07 (6 H, m, -CH₃ × 2),
 1.30 (3 H, t, J = 7.2 Hz, -OCH₂CH₃),
 1.34 - 1.78 (9 H, m),
 3.40 - 3.61 (5 H, m),
 4.28 (2 H, m, -OCH₂CH₃)
 4.48 (1 H, dd, J = 2.0, 7.5 Hz),
 4.67 (1 H, dd, J = 2.0, 7.6 Hz),
 4.89 (1 H, d, J = 7.5 Hz, -OH),
 5.04 (1 H, m, >CHCON<),

7.49 (1 H, d, J = 8.9 Hz, -NHCHCO-)

Example 18

5 Ethyl (4S,5S)-5-[(S)-3-methyl-1-(piperidino-1-yl-carbonyl)butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide




20 Following the same procedures as in Example 4, 90 mg of a target compound were prepared from ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-(piperidine-1-yl-carbonyl)butylcarbamoyl]propionate obtained in Example 17. NMR data of the target compound was as follows.

¹H-NMR (CDCl₃)

25 δ ppm : 0.92 (3 H, d, J = 6.4 Hz, -CH₃),
 0.99 (3 H, d, J = 6.4 Hz, -CH₃),
 1.36 (3 H, t, J = 7.1 Hz, -OCH₂CH₃),
 1.41 - 1.73 (9 H, m),
 3.42 (2 H, br s),
 3.58 (2 H, m),
 30 4.38 (2 H, m, -OCH₂CH₃),
 5.01 (1 H, m, >CHCON<),
 5.45 (1 H, d, J = 3.9 Hz),
 5.52 (1 H, d, J = 3.9 Hz),
 35 7.28 (1 H, br s, -NHCHCO-)

Example 19

Ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-1-decylcarbamoyl-3-methylbutylcarbamoyl]propionate



50 L-leucyldecylamide obtained in Reference Example 6 was reacted following the same procedures as in Example 1, and the obtained compound was reacted following the same procedures as in Example 2, thereby obtaining 1.05 g of a target compound. NMR data of the target compound was as follows.


¹H-NMR (CDCl₃)

55 δ ppm: 0.79 - 1.01 (9 H, m, -CH₃ × 3),
 1.14 - 1.73 (22 H, m),
 3.20 (2 H, m, -NHCH₂-),
 3.52 (1 H, d, J = 7.1 Hz, -OH),
 4.28 (2 H, m, -OCH₂CH₃),
 4.46 (2 H, m),

4.65 (1 H, d, J = 6.9 Hz),
 4.84 (1 H, d, J = 7.2 Hz),
 6.54 (1 H, br s, -CONHCH₂-),
 7.31 (1 H, d, J = 8.5 Hz, -NHCHCO-)

Example 20

Ethyl (4S,5S)-5-[(S)-1-decylcarbamoyl-3-methylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide



Following the same procedures as in Example 4, 286 mg of a target compound were obtained as white crystals from ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-1-decylcarbamoyl-3-methylcarbamoyl]propionate (444 mg) obtained in Example 19. NMR data, SIMS data, and a melting point of the target compound were as follows.


¹H-NMR (CDCl₃)

0.81 - 1.00 (9 H, m, -CH₃ × 3),
 1.18 - 1.70 (18 H, m),
 1.37 (3 H, t, J = 7.1 Hz, -OCH₂CH₃),
 3.27 (2 H, m, -NHCH₂-),
 4.30 - 4.46 (3H, m, -OCH₂CH₃, >CHCONH-),
 5.48 (2 H, dd, J = 3.8, 5.8 Hz),
 5.80 (1 H, br s, -CONHCH₂-),
 6.96 (1 H, d, J = 8.1 Hz, -NHCHCO-)

SIMS m/z; 493 (M + 1)
 mp; 114.0 - 114.6 °C

Example 21

Ethyl (2S,3S)-2,3-dihydroxy-3[(S)-1-cyclohexylcarbamoyl-3-methylbutylcarbamoyl]propionate



L-leucylcyclohexylamide obtained in Reference Example 7 was reacted following the same procedures as in Example 1, and the obtained compound was reacted following the same procedures as in Example 2, thereby obtaining 415 mg of a target compound. NMR data of the target compound was as follows.


¹H-NMR (CDCl₃)

δ ppm : 0.80 - 1.02 (6 H, m, -CH₃ × 2),
 1.09 - 1.38 (5 H, m),
 1.31 (3 H, t, J = 7.2 Hz, -OCH₂CH₃),
 1.50 - 1.91 (8 H, m),

3.51 (1 H, d, J = 7.3 Hz, -OH),
 3.68 (1 H, m),
 4.26 (2 H, m, -OCH₂CH₃),
 4.40 (1 H, m, >CHCONH-),
 4.49 (1 H, d, J = 7.1 Hz),
 4.66 (1 H, dd, J = 1.7, 7.2 Hz),
 4.99 (1 H, d, J = 7.3 Hz, -OH),
 6.41 (1 H, d, J = 8.1 Hz),
 7.34 (1 H, d, J = 8.6 Hz)

Example 22

Ethyl (4S,5S)-5-[(S)-1-cyclohexylcarbamoyl-3-methylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide



Following the same procedures as in Example 4, 151 mg of a target compound were prepared as white crystals from ethyl (2S,3S)-2,3-dihydroxy-3-[(S)-1-cyclohexylcarbamoyl-3-methylbutylcarbamoyl]propionate (415 mg) obtained in Example 21. NMR data and a melting point of the target compound were as follows.


¹H-NMR (CDCl₃)

δ ppm: 0.81 - 1.01 (6 H, m, -CH₃ × 2),
 1.08 - 1.47 (5 H, m),
 1.36 (3 H, t, J = 7.2 Hz, -OCH₂CH₃),
 1.56 - 1.78 (6 H, m),
 1.82 - 1.96 (2 H, m),
 3.74 (1 H, m),
 4.26 - 4.46 (3 H, m, -OCH₂CH₃, >CHCONH-),
 5.50 (2 H, dd, J = 3.9, 7.2 Hz),
 5.74 (1 H, d, J = 8.6 Hz),
 7.10 (1 H, d, J = 8.0 Hz)

mp: 176.7 - 177.1 °C

Example 23

Benzyl (2S,3S)-2,3-dihydroxy-3-[(S)-1-(3-methylbutylcarbamoyl)-2-phenylethylcarbamoyl]proionate




Monobenzyl D-tartrate ester (150 mg) obtained in Reference Example 10 was dissolved in dimethylformamide (6 ml). N-dihydroxysuccinimide (66 mg) and dicyclohexylcarbodiimide (142 mg) were sequentially added to the resultant solution under ice cooling, and the solution was stirred under ice cooling. Thereafter, the temperature was gradually returned to room temperature. After two hours, a dimethylformamide (2 ml) solution of L-phenylalanylisovalamide (146 mg) obtained in Reference Example 8 was added to the resultant solution under ice cooling, and the solution was stirred under ice cooling. The solution was stirred overnight while the temperature was gradually returned to room temperature. The reaction solution was subjected to distillation under a reduced pressure, and ethyl acetate was added. The organic layer was sequentially washed with saturated sodium bicarbonate solution and saturated sodium chloride solution and dried with magnesium sulfate, and the solvent was distilled off under a reduced pressure, thereby obtaining a crude product. This crude product was purified by using a silica gel column chromatography (a developing solvent: chloroform: methanol = 30 : 1) to obtain 220 mg of a target compound. NMR data of the compound was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.69 - 0.90 (6 H, m, -CH₃ × 2),
 1.06 - 1.19 (2 H, m),
 1.22 - 1.39 (1 H, m),
 2.88 - 3.18 (4 H, m),
 3.52 (1 H, d, J = 7.0 Hz),
 4.43 - 4.67 (3 H, m),
 4.71 (1 H, d, J = 6.6 Hz),
 5.20 (1 H, d, J = 12.1 Hz, -CH₂Ph),
 5.26 (1 H, d, J = 12.1 Hz, -CH₂Ph),
 5.85 (1 H, br s, -CONHCH₂-),
 7.08 - 7.38 (10 H, m, arom),
 7.48 (1 H, d, J = 8.0 Hz, -NHCHCO-)

Example 24

Benzyl (4S,5S)-5-[(S)-1-(3-methylbutylcarbamoyl)-2-phenylethylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide



Following the same procedures as in Example 4, 106 mg of a target compound were prepared as white crystals from benzyl (2S,3S)-2,3-dihydroxy-3-[(S)-1-(3-methylbutylcarbamoyl)-2-phenylethylcarbamoyl]-propionate (180 mg) obtained in Example 23. NMR data, SIMS data, and a melting point of the target compound were as follows.

¹H-NMR (CDCl₃)


δ ppm: 0.80 - 0.91 (6 H, m, -CH₃ × 2),
 1.16 - 1.27 (2 H, m),
 1.35 - 1.48 (1 H, m),
 2.97 - 3.28 (4 H, m),
 4.56 (1 H, m, >CHCONH-),
 5.31 (2 H, br s, -CH₂Ph),
 5.32 (1 H, d, J = 4.1 Hz),

5.43 (1 H, d, J = 4.1 Hz),
7.17 - 7.43 (10 H, m, arom)

SIMS m/z; 519 (M + 1)
mp; 147.5 - 148.5 °C

Example 25

Benzyl (2S,3S)-2,3-dihydroxy-3-[(S)-1-(3-methylbutylcarbamoyl)pentylcarbamoyl]propionate




Following the same procedures as in Example 23, 235 mg of a target compound were prepared from monobenzyl D-tartrate ester (166 mg) obtained in Reference Example 10 and L-norleucylisoamylamide (152 mg) obtained in Reference Example 9. NMR data of the target compound was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.79 - 0.94 (9 H, m, -CH₃ × 3),
1.18 - 1.40 (6 H, m),
1.46 - 1.82 (3 H, m),
3.20 (2 H, m, -NHCH₂-),
3.52 (1 H, d, J = 7.2 Hz),
4.35 (1 H, q, J = 7.2 Hz, >CHCONH-),
4.50 (1 H, dd, J = 1.8, 7.2 Hz),
4.65 (1 H, d, J = 7.2 Hz),
4.71 (1 H, dd, J = 1.8, 7.2 Hz),
5.20 (1 H, d, J = 12.2 Hz, -CH₂Ph),
5.26 (1 H, d, J = 12.2 Hz, -CH₂Ph),
6.40 (1 H, t, J = 5.6 Hz, -CONHCH₂-),
7.27 - 7.41 (6 H, m)

Example 26

Benzyl dioxide (4S,5S)-5-[(S)-1-(3-methylbutylcarbamoyl)pentylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-



Following the same procedures as in Example 4, 169 mg of a target compound were prepared as white crystals from benzyl (2S,3S)-2,3-dihydroxy-3-[(S)-1-(3-methylbutylcarbamoyl)pentylcarbamoyl]propionate (205 mg) obtained in Example 25. NMR data of the target compound was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.80 - 0.97 (9 H, m, -CH₃ × 3),
1.20 - 1.44 (6 H, m),
1.55 - 1.90 (3 H, m),


3.28 (2 H, m, -NHCH₂-),
 4.37 (1 H, dd, J = 7.5, 14.3 Hz, >CHCONH-),
 5.32 (2 H, br s, -CH₂Ph),
 5.47 (1 H, d, J = 3.8 Hz),
 5.56 (1 H, d, J = 3.8 Hz),
 5.84 (1 H, t, J = 5.4 Hz, -CONHCH₂-),
 7.18 (1 H, d, J = 8.0 Hz, -NHCHCO-),
 7.34 - 7.47 (5 H, m, arom)

SIMS m/z; 485 (M + 1)

mp; 117.7 - 118.7 °C

Example 27

Benzyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-phenethylcarbamoyl]butylcarbamoyl]propionate




Following the same procedures as in Example 23, 143 mg of a target compound were prepared by condensing (1S,2S)-2-benzyloxycarbonyl-1,2-dihydroxyethanecarbonyl-L-leucine (161 mg) obtained in Reference Example 11 and phenethylamine (57 mg). NMR data of the target compound was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.80 - 0.94 (6 H, m, -CH₃ × 2),
 1.44 - 1.70 (3 H, m),
 2.79 (2 H, t, J = 7.4 Hz, -CH₂CH₂Ph),
 3.33 (1 H, d, J = 7.8 Hz),
 3.52 (2 H, m, -NHCH₂-),
 3.98 (1 H, d, J = 7.8 Hz),
 4.32 - 4.41 (1 H, m, >CHCONH-),
 4.45 (1 H, dd, J = 1.8, 7.8 Hz),
 4.68 (1 H, dd, J = 1.8, 7.8 Hz),
 5.25 (2 H, br s, -CH₂Ph),
 6.23 (1 H, t, J = 6.9 Hz, -CONHCH₂-),
 7.01 (1 H, d, J = 8.9 Hz, -NHCHCO-),
 7.12 - 7.40 (10 H, m, arom)

Example 28

Benzyl (4S,5S)-5-[(S)-3-methyl-1-phenethylcarbamoyl]butylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-dioxide



Following the same procedures as in Example 4, 82 mg of a target compound were prepared as white crystals from benzyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-phenothylcarbamoylbutylcarbamoyl]propionate (109 mg) obtained in Example 27. NMR data, SIMS data, and a melting point of the target compound were as follows.

¹H-NMR (CDCl₃)


δ ppm: 0.81 - 0.98 (6 H, m, -CH₃ × 2),
 1.47 - 1.70 (3H, m),
 2.82 (2 H, d, J = 6.8 Hz, -CH₂CH₂Ph),
 3.56 (2 H, m, -NHCH₂-),
 4.32 (1 H, m, >CHCONH-),
 5.33 (2 H, br s, -CH₂Ph),
 5.40 (1 H, d, J = 3.7 Hz),
 5.49 (1 H, d, J = 3.7 Hz),
 5.77 (1 H, br s, -CONHCH₂-),
 6.82 (1 H, d, J = 8.8 Hz, -NHCHCO-),
 7.10 - 7.50 (10 H, m, arom)

SIMS m/z; 519 (M + 1)

mp; 99.2 - 101.0 °C

Example 29

Benzyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-phenylcarbamoylbutylcarbamoyl]propionate




Following the same procedures as in Example 23, 93 mg of a target compound were obtained by condensing (1S,2S)-2-benzoyloxycarbonyl-1,2-dihydroxyethanecarbonyl-L-leucine (200 mg) obtained in Reference Example 11 and aniline (59 mg). NMR data of the target compound was as follows.

¹H-NMR (CDCl₃)

δ ppm: 0.80 - 1.01 (6 H, m, -CH₃ × 2),
 1.57 - 1.82 (3 H, m),
 3.66 (1 H, d, J = 7.3 Hz),
 4.52 (1 H, d, J = 5.7 Hz),
 4.61 - 4.82 (3 H, m),
 5.12 (1 H, d, J = 12.2 Hz, -CH₂Ph),
 5.20 (1 H, d, J = 12.2 Hz, -CH₂Ph),
 6.97 - 7.56 (11 H, m, -CONHCH< and arom)
 8.99 (1 H, br s, -CONHPh)

Example 30

Benzyl dioxide (4S,5S)-5-[(S)-3-methyl-1-phenylcarbamoylbutylcarbamoyl]-1,3,2-dioxathiolane-4-carboxylate-2,2-



Following the same procedures as in Example 4, 17 mg of a target compound were prepared from benzyl (2S,3S)-2,3-dihydroxy-3-[(S)-3-methyl-1-phenylcarbamoylbutylcarbamoyl]propionate (25 mg) obtained in Example 29. NMR data of the compound was as follows.


¹H-NMR (CDCl₃)

δ ppm: 0.83 - 1.08 (6 H, m, -CH₃ × 2),
 1.52 - 1.81 (3 H, m),
 4.59 - 4.72 (1 H, m),
 5.33 (2 H, br s, -CH₂Ph),
 5.50 (1 H, d, J = 3.6 Hz),
 5.54 (1 H, d, J = 3.6 Hz),
 7.20 - 7.59 (10 H, m, arom)

As has been described above in detail, a 1,3,2-dioxathiolane oxide derivative according to the present invention is a novel compound and can specifically and strongly inhibit thiol proteases without adversely affecting activity of proteolytic enzymes such as trypsin, chymotrypsin, elastase, and leucineaminopeptidase. Therefore, this compound can be used as a prophylactic or curing medicine against, e.g., myotonic dystrophy, inflammation, renal hypertension, cataract, myocardial infarct, a virus infectious disease, a malignant tumor, osteoporosis, and an allergic disease.

Claims


1. A 1,3,2-dioxathiolane oxide derivative represented by the following formula:



(wherein


- X means -S(O)- or -S(O)₂-,
- R¹ means a hydrogen atom, an alkali metal atom, a benzyl group, or a lower alkyl group,
- R² means a lower alkyl group which may be substituted with a methylthio group, or a benzyl group, and
- R³ and R⁴ may be the same or different and independently mean a hydrogen atom, an alkyl group having one to ten carbon atoms, a lower alkyl group substituted with a guanidyl group, a cycloalkyl group having 3 to 6 carbon atoms, a phenyl group, a benzyl group, or a phenethyl group, or together mean an alkylene group.)

2. A 1,2-diol derivative represented by the following formula:



(wherein R¹, R², R³, and R⁴ have the same meanings as defined in claim 1.)

3. A 1,3-dioxolano derivative represented by the following formula:



(wherein

- R¹, R², R³ and R⁴ have the same meanings as defined in claim 1, and
- R⁵ and R⁶ may be the same or different and independently mean a hydrogen atom, a lower alkyl group, a substituted or nonsubstituted phenyl group, a lower alkoxy group, or a lower alkylamino group.)

INTERNATIONAL SEARCH REPORT

International Application No PCT/JP90/01704

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int. Cl ⁵ C07D327/10, C07D317/32, C07C237/22, A61K31/385		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC	C07D327/10, C07D317/32, C07C237/02-22	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ⁶	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	JP, A, 61-227588 (Neos K.K.), October 9, 1986 (09. 10. 86) & Chemical Abstracts Vol. 106, No. 21, p. 731, 176398g	1-3
A	JP, A, 59-7186 (Ota Seiyaku K.K.), January 14, 1984 (14. 01. 84) & Chemical Abstracts Vol. 101, No. 1, p. 7166-7, 7176x	1-3
A	JP, A, 55-115878 (Taisho Pharmaceutical Co., Ltd.), September 6, 1980 (06. 09. 80) & DE, A, 3000628 & US, A, 4333879 & US, A, 4382889	1-3
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"Z" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
March 14, 1991 (14. 03. 91)	March 25, 1991 (25. 03. 91)	
International Searching Authority	Signature of Authorized Officer	
Japanese Patent Office		